Abstract 2237
Background
Docetaxel is an established treatment for pts with mCRPC. Docetaxel plus the programmed death 1 (PD-1) inhibitor pembro and prednisone had activity in patients treated with abi or enza for mCRPC in the phase 1b/2 KEYNOTE-365 study (NCT02861573). KEYNOTE-921 (NCT03834506) is a randomized phase 3 trial to evaluate efficacy and safety of pembro plus docetaxel and prednisone in chemotherapy-naive pts who were previously treated with enza- or abi for mCRPC and had progression while on therapy.
Trial design
Adult (≥18 y) pts with chemotherapy-naive histologically or cytologically confirmed mCRPC who had progression while on androgen deprivation therapy (or postbilateral orchiectomy) within 6 months before screening were eligible. Pts must have had progression after ≥8 wk (≥14 wk for those with bone progression) or become intolerant after ≥4 wk of abi or enza treatment (but not both) with androgen-deprivation therapy in the chemotherapy-naive mCRPC state. Pts must have ECOG PS 0/1, adequate organ function, and tissue for biomarker analysis. Pts will be randomly assigned 1:1 to receive docetaxel 75 mg/m2 every 3 wks (Q3W) plus prednisone/prednisolone 5 mg twice daily (BID) and pembro 200 mg Q3W or docetaxel 75 mg/m2 Q3W plus prednisone/prednisolone 5 mg BID plus placebo Q3W. Treatment will be stratified per prior next-generation hormonal agent treatment (abi/enza) and metastases (bone only/liver/other). Responses will be assessed by CT/MRI and radionuclide bone imaging per PCWG3-modified RECIST v1.1 by blinded independent central review Q9W during the first year and Q12W thereafter. Treatment will continue with docetaxel and prednisone for up to 10 cycles and with pembro for up to 35 cycles or until radiographic disease progression, unacceptable toxicity, or consent withdrawal. Primary end points: overall survival and radiographic progression-free survival. The key secondary efficacy end point is time to initiation of subsequent anticancer therapy or death; safety and tolerability will also be reported. Approximately 1000 pts will be enrolled.
Clinical trial identification
NCT03834506; February 8, 2019.
Editorial acknowledgement
Medical writing and/or editorial assistance was provided by Matthew Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Legal entity responsible for the study
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
D.P. Petrylak: Advisory / Consultancy, Research grant / Funding (institution): Ada Cap (Advanced Accelerator Applications); Advisory / Consultancy: Amgen; Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Clovis; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy: Exelixis; Research grant / Funding (institution): Endocyte; Advisory / Consultancy: Incyte; Research grant / Funding (institution): Innocrin; Advisory / Consultancy: Incyte; Research grant / Funding (institution): Genentech; Advisory / Consultancy: Janssen, Pharmacyclics, Urogen; Research grant / Funding (institution): MedImmune, Merck; Research grant / Funding (institution): Novartis, Progenics, Sanofi Aventis; Advisory / Consultancy, Research grant / Funding (institution): Pfizer, Roche Laboratories, Seattle Genetics; Shareholder / Stockholder / Stock options: Bellicum, Tyme. B. Li: Full / Part-time employment: Merck & Co., Inc. C. Schloss: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc. K. Fizazi: Advisory / Consultancy: Sanofi; Advisory / Consultancy: Amgen; Advisory / Consultancy: Janssen; Advisory / Consultancy: Astellas; Advisory / Consultancy: Orion; Advisory / Consultancy: MSD; Advisory / Consultancy: Bayer.
Resources from the same session
5517 - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: a prospective pilot study.
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 3
Resources:
Abstract
2152 - Inferring the correlation between incidence rates of melanoma and the average tumor-specific epitope binding ability of HLA class I molecules in different populations
Presenter: Istvan Miklos
Session: Poster Display session 3
Resources:
Abstract
4382 - Thermal Liquid Biopsy as a Valuable Tool in Lung Cancer Screening Programs
Presenter: Alberto Rodrigo
Session: Poster Display session 3
Resources:
Abstract
2465 - Towards a screening test for cancer by circulating DNA analysis
Presenter: Rita Tanos
Session: Poster Display session 3
Resources:
Abstract
3788 - Evaluation of a successful launch of the MammaPrint and BluePrint NGS kit
Presenter: Leonie Delahaye
Session: Poster Display session 3
Resources:
Abstract
3863 - Analysis of prognostic factors on overall survival in elderly women treated for early breast cancer using data mining and machine learning
Presenter: Pierre Heudel
Session: Poster Display session 3
Resources:
Abstract
1993 - Circulating tumor cell detection in epithelial ovarian cancer using dual-component antibodies targeting EpCAM and FRα
Presenter: Na Li
Session: Poster Display session 3
Resources:
Abstract
4281 - CEUS of the breast: Is it feasible in improved performance of BI-RADS evaluation of critical breast lesions?——A multi-center prospective study in China
Presenter: Jun Luo
Session: Poster Display session 3
Resources:
Abstract
2268 - Classification of abnormal findings on ring-type dedicated breast PET for detecting breast cancer
Presenter: Shinsuke Sasada
Session: Poster Display session 3
Resources:
Abstract
4035 - Prediction of benign and malignant breast masses using digital mammograms texture features
Presenter: Cui Yanhua
Session: Poster Display session 3
Resources:
Abstract